Di Benedetto F, Magistri P, Di Sandro S, Sposito C, Oberkofler C, Brandon E, et al. Safety and efficacy of robotic vs open liver resection for hepatocellular carcinoma. JAMA Surg. 2023;158(1):46–54.
Chavda V, Zajac KK, Gunn JL, Balar P, Khadela A, Vaghela D, et al. Ethnic differences in hepatocellular carcinoma prevalence and therapeutic outcomes. Cancer Rep (Hoboken). 2023;6(Suppl 1):e1821.
Wang Y, Feng Z, Zhang Y, Zhang Y. Establishment and verification of a prognostic risk score model based on immune genes for hepatocellular carcinoma in an Asian population. Transl Cancer Res. 2023;12(10):2806–22.
Article PubMed PubMed Central Google Scholar
Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Yamamoto Y, et al. Molecular characterization-based multi-omics analyses in primary liver cancer using the Japanese version of the genome atlas. J Hepatobiliary Pancreat Sci. 2023;30(3):269–82.
Kim T, Issa D, Onyshchenko M. Analyzing TCGA data to identify gene mutations linked to hepatocellular carcinoma in Asians. Gastrointest Tumors. 2022;9(2–4):43–58.
Article PubMed PubMed Central Google Scholar
Abenavoli L, Montori M, Svegliati Baroni G, Argenziano ME, Giorgi F, Scarlata GGM, et al. Perspective on the role of gut microbiome in the treatment of hepatocellular carcinoma with immune checkpoint inhibitors. Medicina (Kaunas). 2023;59(8):1427.
Lyubitelev A, Studitsky V. Inhibition of cancer development by natural plant polyphenols: molecular mechanisms. Int J Mol Sci. 2023;24(13):10663.
Article CAS PubMed PubMed Central Google Scholar
Ahmed S, Khan H, Aschner M, Mirzae H, Küpeli Akkol E, Capasso R. Anticancer potential of furanocoumarins: mechanistic and therapeutic aspects. Int J Mol Sci. 2020;21(16):5622.
Article CAS PubMed PubMed Central Google Scholar
Rah B, Farhat NM, Hamad M, Muhammad JS. JAK/STAT signaling and cellular iron metabolism in hepatocellular carcinoma: therapeutic implications. Clin Exp Med. 2023;23(7):3147–57.
Article CAS PubMed Google Scholar
Stagos D, Amoutzias GD, Matakos A, Spyrou A, Tsatsakis AM, Kouretas D. Chemoprevention of liver cancer by plant polyphenols. Food Chem Toxicol. 2012;50(6):2155–70.
Article CAS PubMed Google Scholar
Li S, Yin S, Ding H, Shao Y, Zhou S, Pu W, et al. Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention. Cell Prolif. 2023;56(1):e13346.
Article CAS PubMed Google Scholar
Yang C, Zhang S, Cheng Z, Liu Z, Zhang L, Jiang K, et al. Multi-region sequencing with spatial information enables accurate heterogeneity estimation and risk stratification in liver cancer. Genome Med. 2022;14(1):142.
Article CAS PubMed PubMed Central Google Scholar
Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612(7938):141–7.
Article CAS PubMed Google Scholar
Yu X, Lei X. Application of the multi-omics liquid biopsy method M2P-HCC in early liver cancer screening for high-risk individuals with hepatitis B-related liver cancer. Diagnostics (Basel). 2023;13(15):2484.
Article CAS PubMed Google Scholar
Wang SH, Yeh SH, Chen PJ. Androgen enhances aflatoxin-induced genotoxicity and inflammation to liver cancer in male hepatitis B patients. Cell Mol Gastroenterol Hepatol. 2023;15(2):507–8.
Article CAS PubMed Google Scholar
Xia P, Liu DH, Wang D, Wen GM, Zhao ZY. SLC3A2, as an indirect target gene of ALDH2, exacerbates alcohol-associated liver cancer via the sphingolipid biosynthesis pathway. Free Radic Biol Med. 2023;206:125–33.
Article CAS PubMed Google Scholar
Rodríguez-Lara A, Rueda-Robles A, Sáez-Lara MJ, Plaza-Diaz J, Álvarez-Mercado AI. From non-alcoholic fatty liver disease to liver cancer: microbiota and inflammation as key players. Pathogens. 2023;12(7):940.
Article PubMed PubMed Central Google Scholar
Adugna A. Histomolecular characterisation of hepatitis B virus induced liver cancer. Rev Med Virol. 2023;33(6):e2485.
Article CAS PubMed Google Scholar
Dai W, Shen J, Yan J, Bott AJ, Maimouni S, Daguplo HQ, et al. Glutamine synthetase limits β-catenin-mutated liver cancer growth by maintaining nitrogen homeostasis and suppressing mTORC1. J Clin Invest. 2022;132(24):e161408.
Article CAS PubMed PubMed Central Google Scholar
Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Saitoh S, et al. Favorable impact of serum TERT C228T for prognosis after surgical resection for liver cancer. Oncology. 2023;101(11):738–52.
Article CAS PubMed Google Scholar
Vu T, Fowler A, McCarty N. Comprehensive analysis of the prognostic significance of the TRIM family in the context of TP53 mutations in cancers. Cancers (Basel). 2023;15(15):3792.
Article CAS PubMed Google Scholar
Mou H, Eskiocak O, Özler KA, Gorman M, Yue J, Jin Y, et al. CRISPR-induced exon skipping of β-catenin reveals tumorigenic mutants driving distinct subtypes of liver cancer. J Pathol. 2023;259(4):415–27.
Article CAS PubMed PubMed Central Google Scholar
Schaeffer S, Gupta B, Calatayud AL, Calderaro J, Caruso S, Hirsch TZ, et al. RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis. J Hepatol. 2023;79(3):704–16.
Article CAS PubMed Google Scholar
Lin D, Luo R, Ye Z, Wei Q, Bae H, Juon HS, et al. Genomic characterization of early-stage hepatocellular carcinoma patients with hepatitis B using circulating tumor DNA. Clin Res Hepatol Gastroenterol. 2023;47(7):102161.
Article CAS PubMed Google Scholar
Tümen D, Heumann P, Gülow K, Demirci CN, Cosma LS, Müller M, et al. Pathogenesis and current treatment strategies of hepatocellular carcinoma. Biomedicines. 2022;10(12):3202.
Article PubMed PubMed Central Google Scholar
He J, Han J, Lin K, Wang J, Li G, Li X, et al. PTEN/AKT and Wnt/β-catenin signaling pathways regulate the proliferation of Lgr5+ cells in liver cancer. Biochem Biophys Res Commun. 2023;683:149117.
Article CAS PubMed Google Scholar
Lin W, Wang K, Mo J, Wang L, Song Z, Jiang H, et al. PIK3R3 is upregulated in liver cancer and activates Akt signaling to control cancer growth by regulation of CDKN1C and SMC1A. Cancer Med. 2023;12(13):14413–25.
Article CAS PubMed PubMed Central Google Scholar
You M, Fu J, Lv X, Wang L, Wang H, Li R. Saikosaponin b2 inhibits tumor angiogenesis in liver cancer via down-regulation of VEGF/ERK/HIF-1α signaling. Oncol Rep. 2023;50(1):136.
Article CAS PubMed PubMed Central Google Scholar
Ye JC, Hsieh YS, Chen PN, Liu JY, Hsieh YH. Involvement of matrix metalloproteinase 1 and urokinase-type plasminogen activator in the PKCα-p38 MAPK pathway-mediated progression of human liver cancer cells. Drug Dev Res. 2023;84(4):767–76.
Article CAS PubMed Google Scholar
Yamada K, Hannya Y, Oikawa T, Yoshida A, Katagiri K, Yoshida S, et al. Extended-synaptotagmin 1 enhances liver cancer progression mediated by the unconventional secretion of cytosolic proteins. Molecules. 2023;28(10):4033.
Article CAS PubMed PubMed Central Google Scholar
Kalantari L, Ghotbabadi ZR, Gholipour A, Ehymayed HM, Najafiyan B, Amirlou P, et al. A state-of-the-art review on the NRF2 in Hepatitis virus-associated liver cancer. Cell Commun Signal. 2023;21(1):318.
Article CAS PubMed PubMed Central Google Scholar
Buttell A, Qiu W. The action and resistance mechanisms of Lenvatinib in liver cancer. Mol Carcinog. 2023;62(12):1918–34.
Article CAS PubMed Google Scholar
Abusaliya A, Jeong SH, Bhosale PB, Kim HH, Park MY, Kim E, et al. Mechanistic action of cell cycle arrest and intrinsic apoptosis via inhibiting Akt/mTOR and activation of p38-MAPK signaling pathways in hep3b liver cancer cells by prunetrin-A flavonoid with therapeutic potentiaL. Nutrients. 2023;15(15):3407.
Article CAS PubMed PubMed Central Google Scholar
Li Y, Zhu J, Yu Z, Zhai F, Li H, Jin X. Regulation of apoptosis by ubiquitination in liver cancer. Am J Cancer Res. 2023;13(10):4832–71.
CAS PubMed PubMed Central Google Scholar
Elmetwalli A, Diab T, Albalawi AN, El-Naggar SA, El-Far AH, Ghedan AR, et al. Diarylheptanoids/sorafenib as a potential anticancer combination against hepatocellular carcinoma: the p53/MMP9 axis of action. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(10):2501–17.
留言 (0)